Late ventricular potentials in chronic heart failure patients with preserved ejection fraction
- Authors: Dushina A.G.1, Libis R.A.1
-
Affiliations:
- The Orenburg State Medical University
- Issue: Vol 45, No 3 (2017)
- Pages: 247-253
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/546
- DOI: https://doi.org/10.18786/2072-0505-2017-45-3-247-253
- ID: 546
Cite item
Full Text
Abstract
Rationale: More than half of patients with chronic heart failure have a preserved left ventricular ejection fraction. It has been found that sudden cardiac death is more frequent in this patient category. A reliable and easily available marker is needed that would predict the death outcome with a high probability. The use of the late ventricular potentials for this purpose could be reasonable.
Aim: To assess the prevalence of the late ventricular potential and their association with the structural and functional parameters of the myocardium in patients with early stages of chronic heart failure with preserved ejection fraction.
Materials and methods: We examined 77 patients with chronic heart failure (grade I to IIА, functional class I to III) with preserved ejection fraction (> 50%), aged 47 to 77 years (mean ± SD, 59.7 ± 7.8 years). Echocardiography (SonoScape 8000 and Vivid 3) at М-, В- and Doppler modes was performed in all patients. Ventricular ectopic activity and late ventricular potentials were registered during 24- hour ECG monitoring (Cardiotekhnika, INKART, St. Petersburg).
Results: Late ventricular potentials were found in 13% (10 of 77) of patients. The following correlations were found in patients with concentric hypertrophy (n = 53): between the duration of the filtered QRS (TotORSF) and the left ventricular end diastolic diameter (r = 0.27, p = 0.049), TotORSF and the interventricular septum thickness (r = 0.28, p = 0.04), TotORSF and the left ventricular myocardial mass (r = 0.35, p = 0.01), mean square magnitude of fluctuations within the last 40 ms of ORS (RMS40) and the left ventricular end diastolic diameter (r = -0.42, p < 0.01), RMS40 and the left ventricular end-systolic diameter (r = -0.37, p < 0.01). In the patients with eccentric hypertrophy (n = 14), the following correlations were found: between RMS40 and the left ventricular myocardial mass index (r = -0.77, p < 0.01), between duration of the low amplitude signal (< 40 μV) at the end of QRS (LAS40) and the left ventricular myocardial mass index (r = 0.76, p < 0.01), as well as between LAS40 and RMS40 with the end diastolic diameter of the left ventricle adjusted to the body surface area (r = 0.76, p < 0.01 and r = -0.83, p < 0.01, respectively). The patients with a pseudo normal type of diastolic dysfunction (n = 27) showed an association between their NT-proBNP levels and TotORSF (r = 0.56, p < 0.01).
Conclusion: The prevalence of late ventricular potentials among patients with early stage chronic heart failure and preserved left ventricular ejection fraction is not high. The parameters of electrophysiological myocardial instability in patients with concentric hypertrophy are mostly influenced by the size of heart chambers, whereas in those with the eccentric one, by the myocardial mass and volume parameters. The risk of sudden cardiac death is higher in patients with a pseudo normal type of diastolic dysfunction.
About the authors
A. G. Dushina
The Orenburg State Medical University
Author for correspondence.
Email: al.dushina@yandex.ru
MD, PhD, Assistant, Chair of Hospital Therapy
Clinical City Hospital 1, 23 Gagarina prospect, Orenburg, 460040, Russian Federation. Tel.: + 7 (3532) 35 70 15
РоссияR. A. Libis
The Orenburg State Medical University
Email: fake@neicon.ru
MD, PhD, Professor, Head of Chair of Hospital Therapy
6 Sovetskaya ul., Orenburg, 460000, Russian Federation
РоссияReferences
- Гарднер РС, МакДонаг ТА, Уолкер НЛ. Сердечная недостаточность: пер. с англ. М.: МЕДпресс-информ; 2014. 359 с.
- Мареев ВЮ, Даниелян МО, Беленков ЮН. Сравнительная характеристика больных с ХСН в зависимости от величины фракции выброса по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН: снова о проблеме ХСН с сохранной систолической функцией левого желудочка. Сердечная недостаточность. 2006;7(4): 164–71.
- Cohn JN, Johnson G. Heart failure with normal ejection fraction. The V-HeFT Study. Veterans Administration Cooperative Study Group. Circulation. 1990;81(2 Suppl):III48–53.
- Морозова ЕА, Кивва ВН. Поздние потенциалы желудочков у мужчин пожилого и старческого возраста с метаболическими нарушениями. Фундаментальные исследования. 2004;(3): 76–7.
- Быстров ЯБ, Шубик ЮВ, Чирейкин ЛВ. Поздние потенциалы желудочков в современной диагностике и прогнозе течения заболеваний сердца. Вестник аритмологии. 1999;13:61–74.
- International Diabetes Federation. Worldwide definition of the metabolic syndrome. Available from: http://www.idf.org/e-library/consensus-statements/60-idfconsensus- worldwide-definitionof-the-metabolic-syndrome. Accessed May 3, 2017.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19): 2486–97. doi: 10.1001/jama.285.19.2486.
- Мареев ВЮ, Агеев ФТ, Арутюнов ГП, Коротеев АВ, Мареев ЮВ, Овчинников АГ, Беленков ЮН, Васюк ЮА, Галявич АС, Гарганеева АА, Гиляревский СР, Глезер МГ, Драпкина ОМ, Козиолова НА, Коц ЯИ, Лопатин ЮМ, Мартынов АИ, Моисеев ВС, Ревишвили АШ, Ситникова МЮ, Скибицкий ВВ, Соколов ЕИ, Сторожаков ГИ, Фомин ИВ, Чесникова АИ, Шляхто ЕВ. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013;14(7): 379–472. doi: 10.18087 / rhfj.2013.7.1860.
- Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19(7): 1550–8. doi: https://doi.org/10.1016/0735-1097(92)90617-V.
- Жалюнас Р, Бражджените Ю, Блужайте И. Поздние потенциалы желудочков в остром и восстановительном периодах инфаркта миокарда. Кардиология. 1991;31(2): 56–9.
- Yakubo S, Ozawa Y, Saito S, Kasamaki Y, Komaki K, Hanakawa K, Sasaki Y, Aruga M, Miyazawa I, Kanda T, Sekiguchi K, Shimabukuro H, Nakamura T, Okumura N. Normal limits of high-resolution signal-averaged ECG parameters of Japanese adult men and women. J Electrocardiol. 2000;33(3): 225–31.
- Denes P, Santarelli P, Masson M, Uretz EF. Prevalence of late potentials in patients undergoing Holter monitoring. Am Heart J. 1987;113(1): 33–6.
- Леонова ИА, Болдуева СА. Поздние потенциалы желудочков как один из предикторов внезапной кардиальной смерти у больных после инфаркта миокарда. Вестник аритмологии. 2004;33:12–7.
- Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009;53(11): 905–18. doi: 10.1016/j.jacc.2008.12.007.
- Sanderson JE. Heart failure with a normal ejection fraction. Heart. 2007;93(2): 155–8. doi: 10.1136/hrt.2005.074187.
- Хамуев ЯП. Проблемы диастолической дисфункции левого желудочка: определение, патофизиология, диагностика. Кардиология. 2011;51(11): 71–82.
- Пасечная НА. Оценка влияния структурно-функционального состояния миокарда на возникновение поздних потенциалов желудочков при хронической сердечной недостаточности. Врач-аспирант. 2012;51(2.2): 314–9.
- Искендеров БГ. Электрическая нестабильность сердца при артериальной гипертензии: монография. Пенза; 2009. 208 с.
- Nunez BD, Lavie CJ, Messerli FH, Schmieder RE, Garavaglia GE, Nunez M. Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol. 1994;74(6): 585–9. doi: https://doi.org/10.1016/0002-9149(94)90748-X.
- Palatini P, Maraglino G, Accurso V, Sturaro M, Toniolo G, Dovigo P, Baccillieri S. Impaired left ventricular filling in hypertensive left ventricular hypertrophy as a marker of the presence of an arrhythmogenic substrate. Br Heart J. 1995;73(3): 258–62. doi: http://dx.doi.org/10.1136/hrt.73.3.258.
- Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9): 1278–83. doi: https://doi.org/10.1161/01.CIR.0000054164.99881.00.
- Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis. 2002;44(4): 293–321. doi: https://doi.org/10.1053/pcad.2002.24599.